Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma

BACKGROUND: Despite aggressive upfront treatment in glioblastoma (GBM), recurrence remains inevitable for most patients. Accumulating evidence has identified hypermutation induced by temozolomide (TMZ) as an emerging subtype of recurrent GBM. However, its biological and therapeutic significance has...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniel, Paul, Meehan, Brian, Sabri, Siham, Jamali, Fatemeh, Sarkaria, Jann N, Choi, Dongsic, Garnier, Delphine, Kitange, Gaspar, Glennon, Kate I, Paccard, Antoine, Karamchandani, Jason, Riazalhosseini, Yasser, Rak, Janusz, Abdulkarim, Bassam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252128/
https://www.ncbi.nlm.nih.gov/pubmed/35795471
http://dx.doi.org/10.1093/noajnl/vdac076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252128/
https://www.ncbi.nlm.nih.gov/pubmed/35795471
http://dx.doi.org/10.1093/noajnl/vdac076

Ejemplares similares